Status:
COMPLETED
A Study to Compare 2 Formulations of LY900014 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-70 years
Phase:
PHASE1
Brief Summary
The study involves a comparison of a LY900014 U-200 formulation with a LY900014 U-100 formulation. LY900014 is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two...
Eligibility Criteria
Inclusion
- Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)
- Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)
- Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study
- Have veins suitable for easy blood collection and glucose solution infusion
Exclusion
- Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
- Have previously participated or withdrawn from this study
- Had blood loss of more than 450 milliliters (mL) within the last 3 months
- Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female)
- Smoke more than 10 cigarettes per day
- Are infected with hepatitis B or human immunodeficiency virus (HIV)
- Are taking illegal drugs
Key Trial Info
Start Date :
December 4 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2018
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT03334448
Start Date
December 4 2017
End Date
March 15 2018
Last Update
May 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Singapore, Singapore